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A B S T R A C T
Feline infectious peritonitis (FIP) is a common and highly lethal coronavirus disease of domestic cats. Recent
studies of diseases caused by several RNA viruses in people and other species indicate that antiviral therapy may
be effective against FIP in cats. The small molecule nucleoside analog GS-441524 is a molecular precursor to a
pharmacologically active nucleoside triphosphate molecule. These analogs act as an alternative substrate and
RNA-chain terminator of viral RNA dependent RNA polymerase. We determined that GS-441524 was non-toxic
in feline cells at concentrations as high as 100 uM and effectively inhibited FIPV replication in cultured CRFK
cells and in naturally infected feline peritoneal macrophages at concentrations as low as 1 uM. We determined
the pharmacokinetics of GS-441524 in cats in vivo and established a dosage that would sustain effective blood
levels for 24 h. In an experimental FIPV infection of cats, GS-441524 treatment caused a rapid reversal of disease
signs and return to normality with as little as two weeks of treatment in 10/10 cats and with no apparent
toxicity.
1. Introduction
Feline infectious peritonitis (FIP) is a well-documented infectious
disease of cats, especially kittens, adolescents and young adults from
shelters, kitten foster/rescues and catteries (Pedersen, 2014b). The
causative FIP virus (FIPV) is a positive single stranded RNA virus be-
longing to the family Coronaviridae, species Alphacoronavirus 1, sub-
species feline coronavirus, biotype FIP virus (FIPV) (Tekes and Thiel,
2016).
FIPV infection has a complex immunopathogenesis, a feature shared
by other coronavirus infections (de Wilde et al., 2017), and has become
one of the most researched infectious diseases of cats since its discovery
over a half century ago (Kipar and Meli, 2014; Pedersen, 2014a, 2014b;
Tekes and Thiel, 2016). Despite these advances, modern treatment
options for FIP remain palliative and vaccines have proven either un-
safe or ineffective (Pedersen, 2014b). The emergence of SARS-asso-
ciated coronavirus has provided an impetus for an investment in anti-
viral discovery focused on coronaviruses (De Clercq, 2004). A 3C-like
protease inhibitor (GC376) was first demonstrated to be highly effective
against experimental FIPV infections (Kim et al., 2016). A subsequent
study on cats with naturally acquired FIP showed them to be much
more difficult to treat (Pedersen et al., 2017). Nevertheless, this was the
first study demonstrating the potential for an antiviral compound to
treat FIP in nature and 6 of 20 cats have remained disease free for well
over one year after 12 weeks of treatment (Pedersen et al., 2017).
GS-441524, a 1′-cyano-substituted adenine C-nucleoside ribose
analogue (Fig. 1A ), is a small molecule that exhibits potent antiviral
activity against a number of RNA viruses, including the zoonotic severe
acute respiratory syndrome (SARS) coronavirus (Cho et al., 2012). A
phosphoramidate prodrug of GS-441524 (GS-5734) has been previously
shown to inhibit the replication of several taxonomically diverse RNA
viruses such as Middle East respiratory syndrome virus, Ebola virus,
Lassa fever virus, Junin virus and respiratory syncytial virus, while
having low cytotoxicity in a wide-range of cell lines (Sheahan et al.,
2017). GS-5734 has also been shown to protect rhesus monkeys from
experimental Ebola virus infection (Warren et al., 2016).
GS-441524 requires intracellular phosphorylation via cellular ki-
nases to a nucleoside monophosphate and subsequently to the active
triphosphate metabolite (NTP) (Cho et al., 2012; Sheahan et al., 2017;
Warren et al., 2016) (Fig. 1A). The active NTP analog functions as a
competitor of the natural nucleoside triphosphates in viral RNA
synthesis. The active form of GS-441524 has been shown to inhibit RSV
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RNA-dependent RNA polymerase mediated transcription by in-
corporating into the nascent viral transcript and causing premature
termination (Sheahan et al., 2017). We hypothesized that GS-441524
would be activated in feline cells, attenuate FIPV replication, have low
cytotoxicity in feline cells in vitro and effectively treat cats with ex-
perimentally induced FIP.
2. Materials and methods
2.1. Experimental animals
Specific pathogen free (SPF) cats were purposefully bred in the
Feline Research Laboratory (FRL) breeding colony of the Feline
Nutrition Center, UC Davis. Twelve adolescent cats were used for ex-
perimental infections and six young adult cats for pharmacokinetic
studies. Cats on experiment were housed in open rooms in facilities of
the FRL and cared for by the FRL staff of animal caretakers.
Experiments involving the use of laboratory bred cats were conducted
under UC Davis IACUC protocol #19936. The UC Davis Policy on the
Care and Use of Animals in Teaching and Research requires that
University practices for the procurement, housing, and care and use of
animals must conform to: 1) the ILAR Guide for the Care and Use of
Laboratory Animals; 2) the Guide for the Care and Use of Agricultural
Animals in Research and Teaching; 3) all regulations of the United States
Department of Agriculture (USDA) issued by the USDA implementing
the Animal Welfare Act (AWA) and its amendments (9 CFR, Chapter 3);
and 4) the Public Health Service’s Policy on Humane Care and Use of
Laboratory Animals. In addition, University policy requires that all fa-
cilities in which animals are housed, and the programs associated with
those facilities, must be accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC), International.
2.2. FIPV-79-1146 inoculum for in vitro CRFK infection studies
Crandell-Rees feline kidney (CRFK) cells were propagated in 250ml
flasks with 25ml DMEM/10%FBS and infected at 70% confluency with
1ml cell-culture supernatant containing 5×105 tissue culture
infectious doses-50% (TCID50) per ml of serotype II FIPV WSU-79-1146
(GenBank DQ010921) and incubated for 48 h. Flasks were frozen at
−70 °C for 8min and the thawed mixture of cells and original culture
fluid centrifuged to remove cellular and subcellular debris and super-
natant stored in liquid nitrogen. The level of infectious virus in an
aliquot of the culture supernatant was then determined. CRFK cells
were grown as described above in 24 well plates and infected with one
ml/well of a serial 10-fold dilution of the frozen supernatant. Plates
were then incubated for 48 h, stained with crystal violet (Fig. 1B), and
each well was scored for CPE. A TCID50 was calculated from six re-
plicates by the Reed-Muench method.
2.3. Quantitation of FIPV replication by qRT-PCR
Viral RNA was isolated from both the culture supernatant (QIAamp
Viral RNA Mini Kit (Qiagen) and pelleted cells (RNAeasy, Qiagen) ac-
cording to the manufacturer's instructions. DNase treatment of isolated
RNA was accomplished with TURBO DNase (Ambion). RNA was reverse
transcribed into cDNA with the Origene First-Strand cDNA Synthesis
System for qRT-PCR (Origene). A control reaction excluding reverse
transcriptase was included for each sample. FIPV RNA copy numbers
were measured by qRT-PCR as previously described (Murphy et al.,
2012). PCR primers were based on a consensus sequence of the feline
coronavirus 7b gene. The sequence for the forward primer was 5′-GGA
AGT TTA GAT TTG ATT TGG CAA TGC TAG and the sequence for the
reverse primer 5′-AAC AAT CAC TAG ATC CAG ACG TTA GCT. A
control reaction excluding cDNA (water template) was included for
each assay. Real-time PCR for the GAPDH housekeeping gene (GAPDH)
was performed in parallel and results were normalized per 106 copies of
GAPDH (13). Quantification of FIPV RNA copy number was based on a
standard curve generated from viral transcripts prepared by in vitro
transcription of a plasmid (pCR2.1, Invitrogen) containing a 112 nu-
cleotide-long amplicon.
2.4. GS-441524
GS-441524 was provided by Gilead Sciences, Inc.
Fig. 1. A. Molecular structure of tripho-
sphorylated GS-441524. B. CRFK cell cultures
infected with FIPV-79-1146 showing typical
CPE and crystal violet staining pattern.
Infected cells were treated with 3 uM (row a),
2 uM (row b), 1 uM (row c), 0.75 uM (row d),
0.5 uM (row e), 0.25 uM (row f), 0 uM GS-
441524 (row g); untreated and uninfected cells
(row h). C. A nonlinear regression analysis
utilizing these data determined the EC50 for
GS-441524 to be 0.78 uM.
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2.5. Analysis of cells and body fluids for GS-441524 prodrug and
triphosphate
Proteins in samples of plasma, aqueous humor, and cerebrospinal
fluid (CSF) were precipitated by adding acetonitrile to a final con-
centration of 89% in the presence of an internal standard [20 nM of 5-
(2-Aminopropyl) indole (5-IT)]. Samples were filtered to remove pre-
cipitated protein, dried completely under a stream of nitrogen, and
reconstituted with 0.2% formic acid 1% acetonitrile for LC/MS-MS
analysis for GS-441524 concentrations. Frozen samples of cultured cells
and PBMCs used for triphosphate analysis were resuspended in 0.5 ml
of 70% methanol containing an internal standard (500 nM 2-chloro-
ATP) for at least 30min at −80 °C. The resulting supernatants were
dried in a centrifuging evaporator (Genevac, Stone Ridge, NY) and
samples were reconstituted with an aqueous solution of 1mM ammo-
nium phosphate, pH 7. Analytes were separated using a 50 x 2mm,
2.5 u Luna C18(2) HST column (Phenomenex, Torrance, CA) connected
to a LC-20ADXR (Shimadzu, Columbia, MD) ternary pump system and
HTS PAL autosampler (LEAP Technologies, Carrboro, NC). A multi-
stage linear gradient from 10% to 50% acetonitrile in a mobile phase
containing 3mM ammonium formate (pH 5.0) with 10mM di-
methylhexylamine at a flow rate of 150 u L/min was used to separate
analytes. Detection was performed on an API 5000 (Applied
Biosystems, Foster City, CA) MS/MS operating in positive ion and
multiple reaction monitoring modes. Analytes were quantified using a
7-point standard curve ranging in concentration from 0.274 to 200 pM
that was prepared from extracts of untreated cells.
2.6. Cyotoxicity of GS-441524 for CRFK cells
Cytotoxicity of GS-441524 was assessed using a commercially
available procedure (CellTox Green Cytotoxicity Assay, Promega).
Cytotoxicity was quantified by the intensity of fluorescence as the dye
selectively binds the DNA of apoptotic/necrotic cells. The fluorescence
of CRFK cells in 96 well plates and treated with 100, 33.3, 11.1, 3.7 and
1.2 uM concentrations of GS-441524 was compared to untreated CRFK
cells (negative control) and cells treated with a cell lysing reagent
provided by the manufacturer (positive control).
2.7. GS-441525 inhibition of FIPV replication in CRFK cells and in
naturally infected macrophage cultures
Inhibition of virus replication by GS-441524 in either CRFK cells or
naturally infected peritoneal macrophages was quantitated by visual/
colorimetric inhibition of CPE as well as suppression of viral RNA ex-
pression by qRT-pCR. In the visual method, CRFK cells were grown in
96 well tissue culture plates containing 250 ul DMEM/10%FBS and
1.6×102 cells/well. Cells were infected at 70% confluency with
2.5×104 TCID50 of FIPV-79-1146/well and gently rocked for 60min.
GS-441524 was then added at concentrations ranging from 0.05 to
100 uM. Unattached cells were removed by gentle washing after 48 h
and attached cells fixed with methanol and stained with crystal violet.
Cytopathic effect was measured both visually (Fig. 1B) and by using a
plate scanner for intensity of crystal violet staining. Tissue culture wells
infected with virus alone (positive control) or uninfected wells (nega-
tive control) were run in parallel. CRFK cells for inhibition of viral RNA
assays were cultured in six well plates and infected after 24 h with FIPV
79-1146 as described above, treated with 50, 10, 1.0, 0.1 or 0 uM GS-
441524, and then cultured for a 20 h. Adherent cells were then gently
detached with a cell scraper with the existing medium and culture su-
pernatant freeze-thawed and tested by qRT-PcR. All assays were per-
formed in six well replicates and the concentration of GS-441524 that
inhibited infection by 50% (EC50) was determined by nonlinear re-
gression analysis (PRISM 7, GraphPad).
The ability of GS-441524 to inhibit replication of wild type strains
of FIPV in their natural host cell was determined in an ex vivo manner
using qRT-PCR. Ten ml of ascites fluid was obtained by abdomino-
centesis from two client owned cats with naturally acquired effusive FIP
and enrolled in a separate study (Pedersen et al., 2017). The fluid was
diluted 1:1 with DMEM/10% FBS and aliquoted into two T25 tissue
culture flasks at a volume of 10ml/flask. The cultures were maintained
for 24 h, which allowed peritoneal-type macrophages to attach to the
flask and neutrophils and lymphocytes to remain free in the medium.
The medium with detached cells was replaced, and cultures maintained
for an additional 20 or 72 h. Adherent cells were gently removed with a
cell scraper and medium and cells were freeze-thawed twice aliquots
frozen at −70 °C.
2.8. Pharmacokinetic studies of GS-441524 in cats
A pharmacokinetic (PK) study was performed in laboratory cats to
determine the metabolism and acute animal toxicity of GS-441524. GS-
441524 was dissolved at a concentration of 12.5 mg/ml in 5% ethanol,
30% propylene glycol, 45% PEG 400, 20% water, and adjusted to pH
1.9 with concentrated HCl. Six laboratory cats were randomly divided
into group A (n=3; IV administration) or B (n=3; SC administration).
At time point zero, Group A cats were administered 5mg compound/kg
body weight intravenously while Group B cats received 5mg com-
pound/kg subcutaneously. Cats were then monitored for signs of acute
toxicity (elevated pulse, respiratory distress, cyanosis, diarrhea, anor-
exia, drooling, vomiting, ataxia, weight loss, and changes in rectal
temperature) daily for five days. Serial 0.5 ml whole blood samples in
EDTA were obtained by lateral saphenous, superficial brachial or ju-
gular venipuncture from each cat at 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h.
After collection, blood samples were immediately placed on ice and
then centrifuged at 5000 rpm for 5min. The isolated plasma was pi-
petted into a 1.5 ml microcentrifuge tube and frozen at −70 °C for
further analysis of free GS-441524. The buffy coat fraction from each
blood collection was suspended in 1.5 ml phosphate free Tris-buffered
saline (TBS, 50mM Tris-Cl, pH 7.5, 150mM NaCl) and PBMC isolated
by Ficoll Hypaque density gradient centrifugation. The plasma and
PBMC fractions were snap frozen in liquid nitrogen and shipped on dry
ice to Gilead Sciences, Inc. (Foster City, CA) for further analyses.
(plasma drug concentration and intracellular phosphorylation ana-
lyses).
2.9. Efficacy of GS-441524 against experimental FIP
Twelve six to nine-month-old SPF cats were experimentally infected
by the intraperitoneal route with the cat-passaged serotype I FIPV-m3c-
2 strain. The origin, cat-passage history, preparation of infectious in-
oculum, method of challenge-exposure, and monitoring for disease
signs and response to treatment using this isolate have been previously
reported (Kim et al., 2016; Pedersen et al., 2015). Non-treated control
infection cats were not included, based on humane reasons and his-
torical data on the outcome of identical challenge-exposures (Pedersen
et al., 2015). Fever, absolute lymphopenia, inappetence, jaundice, and
abdominal effusion appear 2–3 weeks after infection in around 80% of
cats and rapidly increase in severity over the next one to two weeks and
would prove fatal if no interventions were taken (Kim et al., 2016;
Pedersen et al., 2015). Cats were treated once a day with either 5mg/kg
(Group A, n= 5) or 2mg/kg (Group B, n= 5) GS-441524 for two
weeks once their disease course became apparent, usually within three
days. Some of the cats were treated with fluid replacement (50m l
lactated Ringer’s solution SC q24 h) and meloxicam (0.2mg/kg PO
q24 h) in this intervening period to prevent undue suffering. Ancillary
treatment was stopped once GS-441524 treatment was instigated. Cats
with recurrent disease signs, usually within four weeks after initial
treatment, were treated with the same regimen for two additional
weeks. All the cats were then observed for a minimum of 8 months for
any recurrence of FIP.
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2.10. Statistics
Data are presented as the mean of three or more values with the
standard deviations displayed as error bars. An analysis of variance was
performed (ANOVA) on each data set. Where global differences were
identified, the Tukey-Kramer multiple comparisons test was utilized for
pair-wise comparisons of the mean responses between treatment
groups. A nonlinear regression analysis was performed for dose re-
sponse data. Statistics were performed with PRISM 7 (GraphPad
Software Inc., La Jolla, CA). A probability value≤ 0.05 was deemed
statistically significant.
3. Results
3.1. GS-441524 was not cytotoxic to CRFK cells at concentrations as high
as 100 uM
Determining the toxicity of GS-441524 to CRFK cells was a pre-
requisite to all other studies. To make this determination, CRFK cells
were treated with 100, 33.3, 11.1, 3.7 or 1.2 uM GS-441524 for 24 h.
The cells appeared and grew normally at all concentrations of GS-
441524 and failed to uptake the fluorescent dye CellTox Green at 24 h
(data not shown). The cytotoxic concentration-50% (CC50) was
therefore> 100 uM. No cytotoxicity (CPE) was observed with CRFK
cells exposed to 10 uM of GS-441524 for a longer period of 72 h, either
visually or by quantitation of crystal violet staining.
3.2. GS-441524 inhibits cytopathic effect in CRFK cells as well as viral
RNA expression in CRFK cells and naturally-infected peritoneal
macrophages
It was crucial to show that GS-441524 inhibited FIPV replication in
cultured cells at a very low concentration. This was done initially by
infecting CRFK cell monolayers with serotype II FIPV-79-1146 and then
treating with GS-441524 at concentrations ranging from none to 3.0 uM
one hour later. The CRFK cells were protected from virus-induced CPE
in a dose-dependent manner when tested 72 h later by crystal violet
staining (Fig. 1B). This experiment was repeated three times with si-
milar results and the effective concentration-50% (EC50) of GS-441524
was calculated to be 0.78 uM (Fig. 1C). Inhibition of FIPV replication by
GS-441524 was also measured by qRT-RCR in CRFK cells infected with
FIPV-79-1146 and exposed one hour later to 50, 10, 1.0, 0.1 and 0 uM
GS-441524 for 20 h (Fig. 2A). Complete inhibition of viral RNA ex-
pression was seen at 50 and 10 uM, partial inhibition at 1.0 uM, and no
inhibition at lower concentrations (p < 0.0001) (Fig. 2A).
The serotype 2 FIPV-79-1146 strain has been adapted in vitro to
grow on a few fibroblastic type cell lines. In comparison, Most FIPV
isolates from nature are serotype 1 and have a specific tropism for
peritoneal-type macrophages. As such, inhibition of FIPV-79-1146 re-
plication in CRFK cells may not parallel the natural condition. To dis-
count this possibility, ex vivo infected peritoneal macrophage cultures
were established from ascites of two unrelated cats with naturally-ac-
quired effusive FIP. Ex vivo cultures from the first cat were treated with
10 uM GS-441524 for 20 h, which resulted in a significant reduction of
cell-associated FIPV RNA transcripts by approximately 1000-fold re-
lative to untreated cells (Fig. 2B). This experiment was repeated with
ascites cells isolated from a second cat with naturally-acquired FIP, but
with the incubation extended to 72 h. These cultures also demonstrated
significant (p < .0012) reduction in cell-associated FIPV RNA relative
to untreated cells (data not shown).
3.3. Effective intracellular levels of non-phosphorylated and phosphorylated
GS-441524 were sustained for three days in CRFK cells exposed to 1 uM GS-
441524
It was important to demonstrate that GS-441524 is internalized by
feline cells, that it is phosphorylated within cells to its active form, and
that pro- and activated-drug levels are sustained. The intracellular le-
vels of non-phosphorylated GS-441524 in CRFK cells exposed to 1 uM of
the prodrug over a three-day period remained steady at 2 to 2.5 pM/
million cells (Fig. 2C). Pharmacologically active triphosphate in these
cultures was also tested and found to hold steady at concentrations
around 1 pM/million cells over the three-day period. The intracellular
volume of a typical cultured mammalian cell averages 1000 fL (1 pL)
(Bryan et al., 2014), which would make the intracellular triphosphate
level in a single cell 1 uM, which is near the EC50 calculated from CRFK
cultures (Fig. 1C).
3.4. Effective blood levels of GS-441524 were sustained over 24 h following
a SC or IV dose of 5 mg/kg and high levels of triphosphate were achieved in
PBMCs
It was essential to determine the metabolism of GS-441524 in cats
prior to animal infections studies. This was done with a standard
pharmacokinetic (PK) study, where two cats were administered 5mg/
kg of GS-441524 subcutaneously and two cats received the same dose
intravenously and plasma and cell (PBMC) levels of pro- and activated-
GS-441524 measured over a defined time. The overall plasma phar-
macokinetic profiles were similar between the subcutaneous and in-
travenous groups (Fig. 2D), with area under the curve (AUC) over 24 h
values of 38.9 and 43.8 uM*hL, respectively. The intracellular tripho-
sphate concentration in PBMC appeared higher in cats administered GS-
441524 by the SC route, but the differences were not significant due to
sample variation and number (Fig. 2E). The concentration of tripho-
sphate in PBMC was sustained at 8–20 times higher than the levels of
the prodrug (Fig. 2E). This was also 8–20 times higher than the EC50 of
1uM calculated by two different methods from CRFK cultures (Figs. 1C
and 2A).
3.5. Concentrations of GS-441524 in aqueous humor and CSF were one-
fifth that of plasma
FIP is well known to involve both the eyes and CNS (Pedersen,
2014b) and it is therefore important to know how well GS-441524
penetrates the blood/brain and blood/eye barriers. Two young adult
cats were given 10mg/kg of GS-441524 SC and two cats were untreated
to provide control fluids. Samples of plasma (venous blood), aqueous
humor (anterior chamber centesis) and CSF (cisterna magnum centesis)
were collected two hours later and prodrug levels compared with
plasma. Levels of the parent GS-441524 were highest in blood (11 and
12.8 uM), lower in ocular aqueous humor (2.4 and 4.3 μM or 22–33% of
plasma), and lowest in the CSF (0.8 and 2.7 uM or 7-21% of plasma).
Combined levels of drug in aqueous humor and CSF averaged 21.4% of
blood plasma.
3.6. Two weeks of GS-441524 treatment at a dosage of 2 or 5 mg/kg SC q
24 h rapidly reversed clinical signs and prevented FIP-associated mortality in
experimentally infected cats
The results of prior cell culture and PK studies indicated that GS-
441524 would be an effective treatment for FIP in cats and suggested an
effective dosage regimen. This was tested in an experimental infection
study where laboratory cats were inoculated intraperitoneally with a
strain of FIPV that has been maintained as near to wild-type as possible
and well characterized in past studies (Kim et al., 2016; Pedersen et al.,
2015). Twelve adolescent laboratory cats were challenge-exposed to
this FIPV and their response to GS-441524 treatment monitored when
terminal disease signs became apparent. Ten of 12 of these cats,
16–113, 16-116, 16-119, 16-123 and 124, 16-127 to 131, demonstrated
clinical signs consistent with FIP within 10-18 days, while two cats (16-
115 and 16-118) remained healthy (Fig. 3). Clinical signs of FIP in the
affected cats started with hyperthermia (> 103 F) (Fig. 4) and
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Fig. 2. GS-441524 inhibits FIPV associated replication in feline cells. A. Viral RNA expression as measured by qRT-PCR (y axis) in FIPV infected CRFK cells treated
with 0 to 50 uM of GS-441524 (x axis). B. Feline peritoneal macrophages derived from ascitic fluid of a naturally FIPV-infected cat and treated with 10 uM GS-
441524 have a 1000-fold reduction in viral copy number relative to untreated cells (p < 0.0001). C. Intracellular concentrations of GS-441524 (O) and its tri-
phosphate form (Δ) following incubation of CRFK cells with 1 uM GS-441524 for 3 days. The intracellular level of tri-phosphorylated GS-441524 was sustained at
approximately 1 pM/million cells. D. Plasma pharmacokinetic profiles of GS-441524 were similar in cats treated subcutaneously or intravenously with 5mg/kg of
GS-441524. E. The intracellular triphosphate concentration in PBMC was 8–20-fold greater in cats treated IV or SC with GS-441524 than the 0.78 uM concentration
necessary to inhibit FIPV replication in CRFK cells by 50%.
Fig. 3. GS-441524 treatment results in FIP re-
mission in experimentally FIPV infected cats.
Ten of 12 SPF cats experimentally infected with
FIPV showed no clinical signs of FIP for
10–17days after challenge-exposure (dashed
line). At that time, they developed fever and
lymphopenia (*). Two cats (16–115 and 16-
118) did not become ill (dashed line). A two-
week treatment course (black line) with either
5mg/kg (group A) or 2 mg/kg (group B) of GS-
441524 was instigated within 2–3 days of dis-
ease onset and resulted in rapid remission of
disease signs (grey line). A recurrence of clin-
ical signs after four and six weeks in two of the
10 treated cats, 16–116 (Group A) and 16–127
(Group B) necessitated a second 2-week course
of treatment (black line). All cats have re-
mained disease free 10 months later at the time
of writing.
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lymphopenia (less than or equal to 1700 cells/ul blood) (Fig. 5), and
then rapidly progressed to depression, anorexia, hyperbilirubinemia,
and ascites. The severity of lymphopenia appeared to be proportional to
the severity of overall disease signs and one cat (16–113) had a mea-
sured nadir of 143 lymphocytes/ul blood (Fig. 5). Rectal temperature
and lymphocyte levels remained normal in the two asymptomatic cats.
The 10 cats that developed disease signs were divided into two
groups and treated with either 5mg/kg (Group A; n=5) or 2mg/kg
(Group B; n= 5) GS-441524 SC q24 h starting three days after un-
equivocal clinical evidence of FIP (days 12–19 post infection)
(Figs. 3–5). The two cats that did not develop disease signs served as
controls for normal blood lymphocyte counts and rectal temperature.
Fig. 4. Virus-associated fever is rapidly nor-
malized by GS-441524 treatment in experi-
mentally FIPV-infected cats. Ten of 12 SPF cats
experimentally infected with FIPV developed
hyperthermia (> 102.5 °F) 10–17 days after
FIPV inoculation (cats 16–113, 16–116,
16–119, 16–123, 16–124, 16–127, 16–128,
16–129, 16–130). Two cats (16-115 and 16-
118) were presumably resistant to disease and
were not treated. Fevers responded rapidly to
GS-441524 treatment regardless of dosage.
Fig. 5. Virus-associated lymphopenia is normalized by GS-441524
treatment in experimentally FIPV-infected cats. Eleven of 12 SPF
cats experimentally infected with FIPV developed lymphopenia
(less than or equal to 1700 cells/ul blood (——————) within
10–17 days after FIPV inoculation (cats 16–113, 16–116, 16–119,
16–123, 16–124, 16–127, 16–128, 16–129, 16–130). Cat 16–118,
which was one of two cats that resisted infection, did not manifest
lymphopenia, while a second resistant cat (16–115) had mild
lymphopenia. Lymphocyte counts returned rapidly to pre-disease
levels, regardless of dosage.
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All 10 treated cats had a rapid response to treatment and lymphocyte
levels and rectal temperatures returned to pre-infection levels and le-
vels of the two asymptomatic cats (Figs. 4,5). Two of the 10 treated
cats, 16–116 (Group A) and 16–127 (Group B), had recurrences disease
at four and six weeks post treatment (Fig. 3). These two cats were
treated a second time for two weeks and their response was identical to
that of primary treatment (data not shown). All ten of the once or twice
treated cats have remained normal to date (more than eight months
post infection). No significant signs of toxicity were noted during or
after primary or secondary treatment. Injections caused a transient
"stinging" reaction in some cats within 10 s of compound administra-
tion. Localized and transient pain was evidenced by unusual posturing,
licking at the injection site and/or vocalizations that lasted for ap-
proximately 30–60 s after injection. Injection reactions were more
pronounced in some animals relative to others and reactions were in-
consistent from one injection to the next and decreased over time.
4. Discussion
The biologic activity of the prodrug GS-441524 against FIPV in-
fection was studied in progressive stages. The initial step involved
screening potential compounds and identifying ones with favorable
EC50 and CC50 values. This was done in vitro using CRFK cells and a
tissue culture adapted serotype II FIPV (FIPV-WSU-79-1146). CRFK
infection experiments identified GS-441524, which had a low EC50
(0.78 uM) against FIPV-79-1146 and no cytotoxicity at the highest
concentrations tested (100 uM). The next step involved an ex vivo ex-
periment using naturally infected peritoneal macrophage cultures es-
tablished from two field cases of effusive FIP. GS-441524 was equally
effective in inhibiting wild-type serotype I FIPV replication in naturally
infected peritoneal cells than it was in inhibiting FIPV-79-1146 in CRFK
cells. Therefore, we anticipated that GS-441524 would also be effective
in cat infection studies against the virulent non-tissue culture adapted
serotype 1 FIPV-m3c-2 strain.
The second stage was to conduct a PK study to rule out acute
toxicities in cats treated with GS-441524 and to determine an optimal
dosage regimen based on blood and tissue distribution. No acute toxi-
cities were observed in laboratory cats after a single SC or IV injection
of GS-441524. Subcutaneous or intravenous dosage at 5mg/kg GS-
441524 resulted in similar plasma profiles and the intracellular tri-
phosphate levels were approximately 8–20 uM in feline PBMCs over a
24 h period. The occurrence of neurological and ocular disease in cats
FIP (Pedersen 2014b), and CNS complications in an earlier trial of a
viral protease inhibitor (Pedersen et al., 2017), was impetus for a
supplementary PK experiment testing the ability of GS-441524 to pass
the blood/eye and blood/brain barriers. A single SC dose of GS-441524
at 10mg/kg resulted in intraocular and CNS drug levels of the parent
GS-441524 that were near or above the effective 1 uM level. Whether
this amount of GS-441524 entering eyes and brain can cure disease in
these sites must await field testing, as it is extremely difficult to recreate
and study ocular and neurologic diseases in the laboratory. GC376, a
3 C-like protease inhibitor, crossed the blood-to-brain barrier at a CSF/
plasma ratio comparative to GS-441524 (Kim et al., 2015), but it was
not effective against pre-existing neurological disease or in preventing
eventual CNS involvement in a proportion of treated cats (Pedersen
et al., 2017).
In the final stage, 12 laboratory-bred cats were experimentally in-
fected with a cat-to-cat passaged serotype 1 strain of FIPV and 10 of
them developed severe disease signs. Five of these ill cats were treated
with 2mg/kg doses of GS-441524 and five with 5mg/kg given sub-
cutaneously every 24 h. A dosage of 5mg/kg of the parent drug sus-
tained blood levels over 24 h in the PK study, which was 8–20 times
higher than an EC50 of the calculated from cell culture experiments.
Therefore, it was reasonable to postulate that 2mg/kg would also be
effective and conserve drug and reduce potential toxicity. The 10
treated cats manifested a rapid reversal of disease signs starting within
24–48 h and comparable between dosages. After two weeks of treat-
ment all 10 cats were well back to normal health and the treatment
stopped. Although no uninfected/untreated control cats were used in
the study, spontaneous recovery is extremely uncommon among either
experimentally induced (Pedersen et al., 2014) or naturally-occurring
FIP (Ritz et al., 2007; Fischer et al., 2011). The results of this cat in-
fection study mirrored our previous experience with a 3C-like protease
(Kim et al., 2016).
Two treated cats, one in each dosage group, experienced disease
relapses at four and six weeks after treatment ended. A second two-
week course of GS-441524 resulted in rapid resolution of disease signs.
Relapses following protease inhibitor treatment (Pedersen et al., 2017)
and experimental infection (de Groot-Mijnes et al., 2005) have been
observed and are most likely due to incomplete clearance of the in-
fection and/or a failure to mount a protective immune response during
infection. The ten treated cats have remained clinically normal to date
(eight months post infection). No systemic signs of drug toxicity were
noted in any of the cats over two-week, and two-week plus a second
two-week, treatment periods.
Studies with tissue cultured cells and laboratory cats strongly sup-
port further testing of GS-441524 in client-owned cats with various
forms of naturally-acquired FIP. An earlier study with a novel 3 C-like
protease inhibitor (GC376), which also underwent the same types of
pre-testing (Pedersen et al., 2017), has provided a template for such a
field trial. Field testing of GC376 demonstrated that naturally occurring
FIPV infection is more difficult to treat than natural infection, may
require a somewhat higher dose, involves many more weeks of treat-
ment, and the cure rate is apt to be lower. Although 19 of the 20 field
cats treated with GC376 regained outward health within two weeks of
treatment, only 6 cats have remained disease free after more than 18
months (Pedersen et al., 2017).
5. Conclusion
The nucleoside analog GS-441524 completely inhibits FIPV re-
plication in CRFK cells and naturally infected feline peritoneal macro-
phages in vitro concentrations≥1 uM and with no detectable toxicity at
100 uM. A dosage regimen was determined from a pharmacokinetic
study in laboratory cats and employed to successfully treat normally
fatal experimentally-induced disease. Nucleoside analogs such as GS-
441524 hold great promise in the treatment of naturally occurring FIP
and may have application to studies of coronavirus infections of other
species.
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